Gyorgy Marko Varga

Summary

Publications

  1. Jankovskaja S, Kamiie J, Rezeli M, Gustavsson L, Sugihara Y, Miliotis T, et al. Optimization of sample preparation for transporter protein quantification in tissues by LC-MS/MS. J Pharm Biomed Anal. 2018;164:9-15 pubmed publisher
    ..We have established an improved transporter protein quantification methodology by optimizing PM isolation and protein digestion procedures. The optimized procedure resulted in a higher transporter protein yield and improved precision. ..
  2. Marcell Szasz A, Malm J, Rezeli M, Sugihara Y, Betancourt L, Rivas D, et al. Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment. Cell Biol Toxicol. 2018;: pubmed publisher
    ..We present data generated by our cancer research center in Lund, Sweden, where we have built extensive capabilities in biobanking, proteogenomics, and patient treatments over an extensive time period. ..
  3. Truedsson M, Malm J, Barbara Sahlin K, Bugge M, Wieslander E, Dahlbäck M, et al. Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. Clin Transl Med. 2016;5:9 pubmed publisher
    ..Such panels of novel biomarkers may be able to distinguish COPD from closely related diseases, co-morbidities, and contribute to an increased understanding of these diseases. Graphical abstract KOL-Örestad Study. ..
  4. Szász A, Gyorffy B, Marko Varga G. Cancer heterogeneity determined by functional proteomics. Semin Cell Dev Biol. 2017;64:132-142 pubmed publisher
    ..In the paper we present current status of Proteomics that we believe requires attention in order to collectively advance forward in the fight against cancer, addressing the burning opportunities and challenges. ..
  5. Bauden M, Kristl T, Sasor A, Andersson B, Marko Varga G, Andersson R, et al. Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma. BMC Cancer. 2017;17:810 pubmed publisher
    ..6 (95% CI 1.1-6.1), p?=?0.029. We suggest that the intratumor histone H1.3 expression as reported herein, may serve as a new epigenetic biomarker for PDAC. ..